Premium
Disposition of Intravenous Pirmenol
Author(s) -
SANDERS STEVEN W.,
NAPPI JEAN M.,
FOLTZ RODGER L.,
LUTZ JOAN REGEDANZ,
ANDERSON JEFFREY L.
Publication year - 1983
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1983.tb02713.x
Subject(s) - medicine , volume of distribution , pharmacokinetics , liter , distribution (mathematics) , urine , clearance , plasma clearance , renal function , anesthesia , urology , mathematical analysis , mathematics
Twelve patients having frequent premature ventricular complexes (PVCs) averaging more than 60 per hour received a single 150‐mg intravenous dose of pirmenol. Plasma pirmenol concentration declined biexponentially following the infusion and was analyzed according to a two‐compartment open model. Following an erratic distribution phase, the terminal elimination half‐life ranged from 4.2 to 16.9 hours, with a geometric mean of 7.6 hours. Total body clearance averaged 164 ± 58 ml/min, and the mean volume of distribution was 1.45 ± 0.38 liter/kg. Renal clearance averaged 46.6 ± 21.2 ml/min, representing 30 ± 10 per cent of total body clearance. Excretion of unchanged drug in the urine averaged 31.8 ± 8 per cent of the dose. Renal clearance and elimination half‐life were correlated ( r = −0.61, P < 0.05). Eight of the 12 patients achieved greater than 95 per cent suppression of PVCs with a duration between 20 minutes and 23 hours. These favorable pharmacokinetics indicate that pirmenol may be a useful addition to the therapy of ventricular arrhythmias.